NCT00651105View on ClinicalTrials.gov

Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Conditions
Type-2 DiabetesHealthy
Interventions
DRUG

Vildagliptin

DRUG

Placebo

Trial Locations (2)

Unknown

Novartis Investigator Site, Bad Lauterberg im Harz

Novartis Investigator Site, Berlin

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY